Chemocentryx, Inc.
SEC CIK 1340652 · CCXI · last insider filing 2022-10-24
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Kanaya Susan M | Director · See Remarks | filed 2012–2022 |
| Feczko Joseph M | Director | filed 2012–2022 |
| Tyree James L | Director | filed 2012–2022 |
| Schall Thomas J. | Director · President, CEO and Director | filed 2012–2022 |
| Parker Geoffrey M. | Director | filed 2012–2022 |
| Edwards Thomas A. | Director | filed 2015–2022 |
| Herron Jennifer Lyn | Director | filed 2022–2022 |
| Jain Rita | Director · EVP, Chief Medical Officer | filed 2019–2022 |
| Wheadon David E. | Director | filed 2022–2022 |
| Mckinnell Henry A | Director | filed 2016–2022 |
| Lucas Roger C | Director | filed 2012–2019 |
| Klein IRA | Director | filed 2013–2015 |
| Penhoet Edward | Director | filed 2012–2013 |
| Gupta Rishi | Director | filed 2012–2012 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Cappel Markus J. | Chief Bus. Officer & Treasurer | filed 2012–2022 |
| Butt Tausif | EVP, Chief Operating Officer | filed 2021–2022 |
| YAU YI Ching | SVP, Finance & Acctg Officer | filed 2022–2022 |
| Kwan Pui San | Principal Acctg Officer | filed 2018–2021 |
| Singh Rajinder | SVP, Research | filed 2016–2019 |
| Fairey William | Chief Operating Officer | filed 2018–2018 |
| Bekker Petrus | SVP of Medical & Clinical | filed 2012–2017 |
| Duliege Anne-Marie | EVP, Chief of Strategic Dev. | filed 2014–2014 |
| Charo Israel | SVP, Research | filed 2014–2014 |
| Jaen Juan C. | SVP, Drug Discovery & CSO | filed 2012–2013 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.